J
Jeffrey A. Morgan
Researcher at Harvard University
Publications - 89
Citations - 8907
Jeffrey A. Morgan is an academic researcher from Harvard University. The author has contributed to research in topics: Sunitinib & GiST. The author has an hindex of 39, co-authored 88 publications receiving 8098 citations. Previous affiliations of Jeffrey A. Morgan include Brigham and Women's Hospital & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri,Allan T. van Oosterom,Christopher R. Garrett,Martin E. Blackstein,Manisha H. Shah,Jaap Verweij,Grant A. McArthur,Ian Judson,Michael Heinrich,Jeffrey A. Morgan,Jayesh Desai,Christopher D.M. Fletcher,Suzanne George,Carlo L. Bello,Xin Huang,Charles M. Baum,Paolo G. Casali +16 more
TL;DR: A randomised, double-blind, placebo-controlled, multicentre, international trial to assess tolerability and anticancer efficacy of sunitinib in patients with advanced gastrointestinal stromal tumour, noting significant clinical benefit, including disease control and superior survival.
Journal ArticleDOI
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu,Tammy F. Chu,Maria Rupnick,Maria Rupnick,Risto Kerkelä,Susan M. Dallabrida,David Zurakowski,Lisa Nguyen,Kathleen C. Woulfe,Elke Pravda,Flavia Cassiola,Jayesh Desai,Suzanne George,David M. Harris,Nesreen S. Ismail,Jey-Hsin Chen,Frederick J. Schoen,Annick D. Van den Abbeele,George D. Demetri,Thomas Force,Ming-Hui Chen,Ming-Hui Chen,Jeffrey A. Morgan +22 more
TL;DR: Left ventricular dysfunction might be due, in part, to direct cardiomyocyte toxicity, exacerbated by hypertension, and patients treated with sunitinib should be closely monitored for hypertension and LVEF reduction, especially those with a history of coronary artery disease or cardiac risk factors.
Journal ArticleDOI
Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors
Chandrajit P. Raut,Matthew Posner,Jayesh Desai,Jeffrey A. Morgan,Suzanne George,David Zahrieh,Christopher D.M. Fletcher,George D. Demetri,Monica M. Bertagnolli +8 more
TL;DR: Patients with advanced GISTs exhibiting stable disease or limited progression on kinase inhibitor therapy have prolonged overall survival after debulking procedures, suggesting surgery has little to offer in the setting of generalized progression.
Journal ArticleDOI
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
Jayesh Desai,Leila Yassa,Ellen Marqusee,Suzanne George,Mary C. Frates,Ming-Hui Chen,Jeffrey A. Morgan,Samuel S. Dychter,P. Reed Larsen,George D. Demetri,Erik K. Alexander +10 more
TL;DR: Biochemical findings of thyroid dysfunction in a patient treated with sunitinib for recurrence of gastrointestinal stromal tumor and patient-reported fatigue noted during clinical trials led to the monitoring of serum thyroid-stimulating hormone (TSH) concentrations to rule out primary hypothyroidism.
Journal ArticleDOI
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
Suzanne George,J.-Y. Blay,Paolo G. Casali,A. Le Cesne,P. Stephenson,Samuel E. DePrimo,Charles S. Harmon,C.N.J. Law,Jeffrey A. Morgan,Isabelle Ray-Coquard,V. Tassell,Darrel P. Cohen,George D. Demetri +12 more
TL;DR: For patients with imatinib-resistant/intolerant GIST, continuous daily sunitinib dosing appears to be an active alternative dosing strategy with acceptable safety.